Cancer predisposing BARD1 mutations in breast-ovarian cancer families

[1]  F. Bertucci,et al.  BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer , 2010, Genes, chromosomes & cancer.

[2]  D. Januszkiewicz-Lewandowska,et al.  RAD50 gene mutations are not likely a risk factor for breast cancer in Poland , 2010, Breast Cancer Research and Treatment.

[3]  Willy Lissens,et al.  Cancer predisposing missense and protein truncating BARD1 mutations in non‐BRCA1 or BRCA2 breast cancer families , 2010, Human mutation.

[4]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[5]  Kylie L. Gorringe,et al.  BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer , 2008, Breast Cancer Research and Treatment.

[6]  P. Brzovic,et al.  Crystal Structure of the BARD1 Ankyrin Repeat Domain and Its Functional Consequences*♦ , 2008, Journal of Biological Chemistry.

[7]  B. Ponder,et al.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[8]  P. Liberski,et al.  Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53 , 2008, British Journal of Cancer.

[9]  S. Ryser,et al.  Oncogenic BARD1 isoforms expressed in gynecological cancers. , 2007, Cancer research.

[10]  Katri Pylkäs,et al.  A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.

[11]  A. Jakubowska,et al.  BARD1 and breast cancer in Poland , 2007, Breast Cancer Research and Treatment.

[12]  Tom Walsh,et al.  Ten genes for inherited breast cancer. , 2007, Cancer cell.

[13]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[14]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[15]  Michael Q. Zhang,et al.  An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. , 2006, Human molecular genetics.

[16]  D. Baralle,et al.  NF1 mRNA biogenesis: Effect of the genomic milieu in splicing regulation of the NF1 exon 37 region , 2006, FEBS letters.

[17]  A. Kluska,et al.  Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland , 2006, International journal of cancer.

[18]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[19]  Heli Nevanlinna,et al.  BARD1 variants Cys557Ser and Val507Met in breast cancer predisposition , 2006, European Journal of Human Genetics.

[20]  Torsten Schwede,et al.  BIOINFORMATICS Bioinformatics Advance Access published November 12, 2005 The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling , 2022 .

[21]  A. Spurdle,et al.  Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer , 2005, Breast Cancer Research.

[22]  D. Baralle,et al.  Splicing in action: assessing disease causing sequence changes , 2005, Journal of Medical Genetics.

[23]  M. Sauer,et al.  Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer , 2005, Journal of Medical Genetics.

[24]  R. Winqvist,et al.  Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer , 2004, Journal of Medical Genetics.

[25]  Karl Sperling,et al.  Increased cancer risk of heterozygotes with NBS1 germline mutations in poland , 2004, International journal of cancer.

[26]  C. Jefford,et al.  Nuclear–cytoplasmic translocation of BARD1 is linked to its apoptotic activity , 2004, Oncogene.

[27]  Stefan Schüchner,et al.  Nuclear–cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1 , 2004, Oncogene.

[28]  R. Winqvist,et al.  Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility , 2003, Journal of medical genetics.

[29]  M. Monden,et al.  Mutational analysis of BARD1 in familial breast cancer patients in Japan. , 2003, Cancer letters.

[30]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[31]  T. Ludwig,et al.  Loss of Bard1, the Heterodimeric Partner of the Brca1 Tumor Suppressor, Results in Early Embryonic Lethality and Chromosomal Instability , 2003, Molecular and Cellular Biology.

[32]  P. Bork,et al.  Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.

[33]  Olufunmilayo I Olopade,et al.  BRCA2 T2722R is a deleterious allele that causes exon skipping. , 2002, American journal of human genetics.

[34]  Massimo Caputi,et al.  A nonsense mutation in the fibrillin-1 gene of a Marfan syndrome patient induces NMD and disrupts an exonic splicing enhancer. , 2002, Genes & development.

[35]  I. Irminger-Finger,et al.  BRCA1-dependent and independent functions of BARD1. , 2002, The international journal of biochemistry & cell biology.

[36]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[37]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[38]  A. Krainer,et al.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 , 2002, Nature Genetics.

[39]  E. Sensi,et al.  Germline mutations of the BRCA1‐associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations , 2002, Genes, chromosomes & cancer.

[40]  N E Day,et al.  A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.

[41]  N E Day,et al.  Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population‐based study , 2001, Genetic epidemiology.

[42]  S. Henikoff,et al.  Predicting deleterious amino acid substitutions. , 2001, Genome research.

[43]  D. Sgroi,et al.  BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function , 2001, Cell.

[44]  S. Antonarakis,et al.  Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2000 .

[45]  D. Easton.  How many more breast cancer predisposition genes are there? , 1999, Breast Cancer Research.

[46]  S. Smerdon,et al.  The ankyrin repeat: a diversity of interactions on a common structural framework. , 1999, Trends in biochemical sciences.

[47]  X. Estivill,et al.  Prenatal diagnosis of sporadic neurofibromatosis type 1 (NF1) by RNA and DNA analysis of a splicing mutation , 1999, Prenatal diagnosis.

[48]  Sara G. Becker-Catania,et al.  Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. , 1999, American journal of human genetics.

[49]  M. King,et al.  Mapping the Functional Domains of BRCA1 , 1999, The Journal of Biological Chemistry.

[50]  A. Bowcock,et al.  Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein , 1998, Oncogene.

[51]  B. Trask,et al.  Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. , 1998, Human molecular genetics.

[52]  David Haussler,et al.  Improved splice site detection in Genie , 1997, RECOMB '97.

[53]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[54]  Peter G. Korning,et al.  Splice Site Prediction in Arabidopsis Thaliana Pre-mRNA by Combining Local and Global Sequence Information , 1996 .

[55]  Junzhe Xu,et al.  The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues , 1995, Nature Genetics.

[56]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[57]  D Morrell,et al.  Incidence of cancer in 161 families affected by ataxia-telangiectasia. , 1991, The New England journal of medicine.

[58]  I. Irminger-Finger,et al.  Identification of BARD1 splice-isoforms involved in human trophoblast invasion. , 2007, The international journal of biochemistry & cell biology.

[59]  M. Ringnér,et al.  Gene expression in inherited breast cancer. , 2002, Advances in cancer research.